NAPU Napo Pharm Di

RNS Number:0749T
Napo Pharmaceuticals Inc
24 April 2008


For immediate release                                           24 April 2008

                            Napo Pharmaceuticals Inc.
                            ("Napo" or "the Company")

                                 Share Purchase


Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR
FROM THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

South San Francisco, California,   (24) April 2008 - South San Francisco,
California, Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), announces that in
relation to transactions of Directors and Persons Discharging Managerial
Responsibility, it was informed on 24 April 2008 that Lisa Conte, CEO of Napo,
purchased 100,000 Common Shares (LSE: NAPL) at a price of 3.5 pence per share.

These shares were purchased on 23 April 2008. Following the purchase of these
Common Shares, Lisa Conte has a total personal holding of 100,000 Common Shares
in the Company amounting to 0.2 per cent of the issued share capital.

Ms. Conte has a deemed interest in 527,746 shares of Common Shares which are
held by Lucy A. Rechseit as Trustee for the Lisa A. Conte 2006 Children's Trust
DTD.  This is an irrevocable trust.


For more information please contract:


Napo Pharmaceuticals, Inc.
Lisa Conte, Chief Executive Officer
(001) + 650 616 1902


Charles Thompson, Chief Financial Officer
(001) + 650 616 1903


Buchanan Communications
(44) + 020 7466 5000
Tim Anderson, Mary-Jane Johnson, Catherine Breen



About Napo Pharmaceuticals, Inc.

Napo Pharmaceuticals, Inc. focuses on the development and commercialisation of
proprietary pharmaceuticals for the global marketplace in collaboration with
local partners. Napo was founded in November 2001, and is based in California,
USA with a subsidiary in Mumbai, India.

Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in
various stages of clinical development for four distinct product indications,
including a late-stage Phase 3 program:


   CRO-HIV for AIDS diarrhoea, Phase 3
   CRO-IBS for diarrhoea irritable bowel syndrome ("D-IBS"), Phase 2
   CRO-ID for acute infectious diarrhoea (including cholera), Phase 2
   CRO-PED for paediatric diarrhoea, Phase 1


The FDA has granted fast-track status to CRO-IBS and CRO-HIV.

Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a
medicinal plant which can be sustainably harvested from several countries in
South America. Napo also plans to develop an early clinical stage product,
NP-500, for the treatment of insulin resistant diseases of Type II diabetes and
metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant
library of approximately 2,300 medicinal plants from tropical regions, and Napo
has entered two screening relationship associated with this collection.

Currently, products are based on the chemical and biological diversity derived
from plants with medicinal properties, but future products may be in-licensed
from other sources.

Napo has partnerships with Glenmark Pharmaceuticals Limited of India and
AsiaPharm Group Ltd. of China.


For more information please visit www.napopharma.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RDSEASLLALPPEFE

Napo Pharm Di (LSE:NAPU)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Napo Pharm Di (LSE:NAPU)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024